Loading…

Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging

Although MR spectroscopic imaging (MRSI) of the prostate has demonstrated clinical utility for the staging and monitoring of cancer extent, current acquisition methods are often inadequate in several aspects. Conventional 180° pulses can suffer from chemical shift misregistration, and have high peak...

Full description

Saved in:
Bibliographic Details
Published in:Magnetic resonance in medicine 2001-12, Vol.46 (6), p.1079-1087
Main Authors: Schricker, Amir A., Pauly, John M., Kurhanewicz, John, Swanson, Mark G., Vigneron, Daniel B.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although MR spectroscopic imaging (MRSI) of the prostate has demonstrated clinical utility for the staging and monitoring of cancer extent, current acquisition methods are often inadequate in several aspects. Conventional 180° pulses can suffer from chemical shift misregistration, and have high peak‐power requirements that can exceed hardware limits in many prostate MRSI studies. Optimal water and lipid suppression are also critical to obtain interpretable spectra. While complete suppression of the periprostatic lipid resonance is desired, controlled partial suppression of water can provide a valuable phase and frequency reference for data analysis and an assessment of experimental success in cases in which all other resonances are undetectable following treatment. In this study, new spectral‐spatial RF pulses were developed to negate chemical shift misregistration errors and to provide dualband excitation with partial excitation of the water resonance and full excitation of the metabolites of interest. Optimal phase modulation was also included in the pulse design to provide 40% reduction in peak RF power. Patient studies using the new pulses demonstrated both feasibility and clear benefits in the reliability and applicability of prostate cancer MRSI. Magn Reson Med 46:1079–1087, 2001. © 2001 Wiley‐Liss, Inc.
ISSN:0740-3194
1522-2594
DOI:10.1002/mrm.1302